MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Creatine for patients with Parkinson’s disease: A meta-analysis

    A. Attia, H. Ahmed, M. Morsi, K. Awad, M. Elnenny, E. Ghanem, A. Negida (Cairo, Egypt)

    Objective: The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of creatine for…
  • 2016 International Congress

    Upper limb motor tests are related to clinical ratings of motor function in advanced Parkinson’s disease

    M. Memedi, S. Aghanavesi, D. Nyholm, H. Askmark, S.M. Aquilonius, R. Constantinescu, F. Bergquist, A. Medvedev, A. Ericsson, F. Ohlsson, S. Lycke, J. Spira, M. Senek, J. Westin (Falun, Sweden)

    Objective: The aim of this study was to investigate whether upper limb motor tests are related to clinical ratings of motor function in Parkinson's disease…
  • 2016 International Congress

    Objective measurement in clinical care of patients with Parkinson’s disease

    M. Horne, K. Kotschet, M. Braybrook (Parkville, Australia)

    Objective: To establish whether using the Parkinson's KinetiGraph™ which provides objective measures in activities of daily living, helps identify unknown poorly controlled patients with Parkinson's…
  • 2016 International Congress

    The NIC-PD-study –Baseline data of a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson’s disease in Germany and the USA

    W.H. Oertel, C. Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, H. Mueller, M.M. Unger, K.M. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

    Objective: The primary endpoint of clinical progression is measured by change in the total UPDRS score between baseline and 1) after 52 weeks of study…
  • 2016 International Congress

    Motor phenotype classification in moderate to advanced PD: Data from the BioFIND study

    L. Luo, H.F. Andrews, J.G. Goldman, R.N. Alcalay, T. Xie, P. Tuite, C. Henchcliffe, P. Hogarth, A. Amara, S. Frank, A. Rudolph, C. Casaceli, K. Gwinn, M. Sutherland, C. Kopil, L. Vincent, M. Frasier, U.J. Kang (New York, NY, USA)

    Objective: To evaluate the validity of motor phenotype classification in response to dopaminergic agents in moderate to advanced Parkinson's disease (PD) patients enrolled in the…
  • 2016 International Congress

    Whole body vibration therapy with exercise enhances motor function and improves quality of life in Parkinson’s disease

    O.K. Gruder, D.Y. Edmonston, G.Q. Barr, C.G. Maitland (Tallahassee, FL, USA)

    Objective: To evaluate the short term effects of whole body vibration and exercise in patients with Parkinson's disease on overall quality of life, gait, tremor,…
  • 2016 International Congress

    Critical path for Parkinson’s, I: Data sharing and regulatory science in catalyzing innovation for Parkinson’s disease

    K. Romero, D. Burn, M. Hu, A. Yarnell, C. Williams Gray, K. Marek, D. Grosset, M. Sutherland, M. Isaac, A. Bhattaram, V. Sinha, M.F. Gordon, P. Muglia, L. Slicker, W. Hirst, M. Facheris, J. Posener, M. Bani, B. Corrigan, R. Schindler, K. Tsai, T. Nicholas, J. Cedarbaum, J. Gallagher, S. Ford, E. Avilex, V. Kern, S. Arneric, D. Stephenson, A. Roach (Tucson, AZ, USA)

    Objective: This presentation highlights a new precompetitive consortium based strategy for the successful development of regulatory-endorsed biomarkers and quantitative drug development platforms targeted at the…
  • 2016 International Congress

    Can hospital admissions predict mortality in Parkinson’s?

    B. Mohamed, N. Leopold, C. Thomas (Cardiff, United Kingdom)

    Objective: Profile patients with Parkinson's who experience inpatient care. Assess the impact of admissions to hospital and evaluate readmissions and mortality rates. Background: People with…
  • 2016 International Congress

    A randomized clinical trial of atomoxetine treatment for mild cognitive impairment (MCI) in Parkinson’s disease (PD)

    V.K. Hinson, J. Elm, A. Delambo, T. Turner (Charleston, SC, USA)

    Objective: To evaluate (1) safety and tolerability of ATM and (2) effects of ATM on attention and executive functioning in PD- MCI after 10 weeks…
  • 2016 International Congress

    STEADY-PD III. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease. Baseline characteristics of the enrolled cohort

    T. Simuni, K.M. Biglan, J. Lowell, K. Hodgeman, B. Greco, R. Rockhill, D. Oakes (Chicago, IL, USA)

    Objective: To evaluate the efficacy of isradipine 10 mg daily on PD disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration of the…
  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley